We are live on ! Find out more
CATX icon

Perspective Therapeutics

97 hedge funds and large institutions have $146M invested in Perspective Therapeutics in 2025 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 40 increasing their positions, 22 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

19,000% more call options, than puts

Call options by funds: $382K | Put options by funds: $2K

82% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 22

52% more capital invested

Capital invested by funds: $96.4M → $146M (+$49.9M)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

3.9% less ownership

Funds ownership: 61.14%57.23% (-3.9%)

13% less funds holding

Funds holding: 11297 (-15)

63% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 24

Holders
97
Holders Change
-15
Holders Change %
-13.39%
% of All Funds
1.27%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
9
Increased
40
Reduced
22
Closed
24
Calls
$382K
Puts
$2K
Net Calls
+$380K
Net Calls Change
+$310K

CATX Hedge Fund Activity: Q2 2025 in Review

97 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Perspective Therapeutics (CATX) for Q2 2025, worth a combined $146M — up 52% from $96.4M a quarter earlier.

Sellers outnumbered buyers: 24 funds closed out of CATX and 9 opened new positions — a net loss of 15 holders — while 22 trimmed existing stakes and 40 added.

The largest buyer was Millennium Management, adding an estimated $6.56M. The largest seller was Deerfield Management, exiting entirely with an estimated $6.03M sold.

  • 97 institutional investors held Perspective Therapeutics (CATX) as of Q2 2025, down from 112 in Q1 2025.
  • Funds reported $146M of Perspective Therapeutics stock for Q2 2025, up 52% quarter-over-quarter.
  • 9 funds opened new Perspective Therapeutics positions in Q2 2025 and 24 closed out, a net change of -15 holders.
  • The largest Perspective Therapeutics buyer in Q2 2025 was Millennium Management, an estimated $6.56M added.
  • The largest Perspective Therapeutics seller in Q2 2025 was Deerfield Management, an estimated $6.03M sold.

Based on aggregated 13F filings for Q2 2025.